Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass
B. Keymeulen, M. Walter, C. Mathieu, L. Kaufman, F. Gorus, R. Hilbrands, E. Vandemeulebroucke, U. Van De Velde, L. Crenier, C. De Block, S. Candon, H. Waldmann, A. G. Ziegler, L. Chatenoud, D. Pipeleers
Research output: Contribution to journal › Article › peer-review
290Scopus
citations
Fingerprint
Dive into the research topics of 'Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass'. Together they form a unique fingerprint.